Skip to content
DraconiticResearch
Search Sources API
197,785 studies31 sourcesUpdated 32 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

605 Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)

  • Drew Rasco1
  • Meredith McKean2
  • Ramaswamy Govindan3
  • Nehal Lakhani4
  • Sophia Frentzas5
  • Andrew Weickhardt6
  • Inbar Amit7
  • Aron Knickerbocker8
  • Yanay Ofran7
  • Jenny Tang8
  • Lori Richards8
  • Catherine Oakman9
6 more authors
  • George R Blumenschein10
  • John D Powderly11
  • Eric Lander12
  • Jeffrey T Yorio13
  • Timothy L Wyant14
  • James R Vasselli15
15 affiliations
  1. 14START San Antonio, San Antonio, TX, USA
  2. 221Sarah Cannon Research Institute, Nashville, TN, USA
  3. 33Washington University School of Medicine, St. Louis, MO, USA
  4. 4START Midwest, Grand Rapids, MI, USA
  5. 52Department of Medical Oncology, Monash Health, Clayton, VIC, Australia
  6. 65Austin Health, Heidelberg, VIC, Australia
  7. 716Biolojic Design, Rehovot, Israel
  8. 815Aulos Bioscience, Larkspur, CA, USA
  9. 912Western Health, Sunshine Hospital, St Albans, VIC, Australia
  10. 10The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  11. 11Carolina BioOncology Institute, PLLC, Huntersville, NC, USA
  12. 12Minnesota Oncology and Hematology, Minneapolis, MN, USA
  13. 13Texas Oncology, Austin, TX, USA
  14. 14Biolojic Design Inc, Cambridge, MA, USA
  15. 15Aulos Bioscience, San Francisco, CA, USA
Open at sourcePDFDOICite

Related

  1. 611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study
    Andrew Haydon, Jose Lutzky, Siwen Hu-Lieskovan +17
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  2. Comparison of subcutaneous and intravenous administration of the monoclonal antibody CSX-1004 on fentanyl-induced respiratory depression in squirrel monkeys
    Mukesh Kumar, Emily L. Burke, Yanan Zang +3
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyFrontiersCrossrefDOAJ
  3. Treatment Optimization with Add-On Kampo Therapy in Highly Refractory Migraine Patients with Inadequate Response or Re-Worsening During CGRP Monoclonal Antibody Therapy: A Real-World Treatment Episode Analysis
    Takafumi Tanei, Satoshi Yamashita, Satoshi Maesawa +6
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  4. Newly developed monoclonal antibodies for marmoset immunosuppression enable KSHV lytic replication and salivary shedding: A promising model for KSHV pathogenesis studies
    Li Han, Esther Rodriguez, Caitlin Shaw +11
    PLOS PathogensPeer-reviewedCC BY 4.0Full textCell biologyImmunologyPLOSPMC
  5. UPDATED RESULTS FROM THE PHASE 2 IZALCO STUDY: EFFICACY AND SAFETY OF ISATUXIMAB SUBCUTANEOUS PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Marcelo CAPRA, Gurdeep PARMAR, Fernanda SEGURO +12
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textEndocrinology & metabolismDOAJ

Cite

BibTeXRIS
BibTeX
@article{rasco2026imneskibart,
  title = {{605 Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)}},
  author = {Drew Rasco and Meredith McKean and Ramaswamy Govindan and Nehal Lakhani and Sophia Frentzas and Andrew Weickhardt and Inbar Amit and Aron Knickerbocker and Yanay Ofran and Jenny Tang and Lori Richards and Catherine Oakman and George R Blumenschein and John D Powderly and Eric Lander and Jeffrey T Yorio and Timothy L Wyant and James R Vasselli},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0605},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0605},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 605 Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)
AU  - Drew Rasco
AU  - Meredith McKean
AU  - Ramaswamy Govindan
AU  - Nehal Lakhani
AU  - Sophia Frentzas
AU  - Andrew Weickhardt
AU  - Inbar Amit
AU  - Aron Knickerbocker
AU  - Yanay Ofran
AU  - Jenny Tang
AU  - Lori Richards
AU  - Catherine Oakman
AU  - George R Blumenschein
AU  - John D Powderly
AU  - Eric Lander
AU  - Jeffrey T Yorio
AU  - Timothy L Wyant
AU  - James R Vasselli
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0605
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0605
SN  - 2051-1426
ER  -